Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab for preventing GPP flares
NCT04399837Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial of spesolimab in generalized pustular psoriasis (GPP) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to First Generalized Pustular Psoriasis Flare at 48 weeks. Started Jun 2020; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT04399837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04399837.